Lin, Yu-WeiYu-WeiLinSHIN-JOE YEHSUNG-CHUN TANGLI-KAI TSAIJIANN-SHING JENG2023-12-132023-12-132022-12-301028-768Xhttps://scholars.lib.ntu.edu.tw/handle/123456789/637799Perihematomal edema of intracerebral hemorrhage (ICH) is caused by a hematoma-induced inflammatory reaction, which usually contributes to delayed deterioration of neurological function and poor outcomes. Celecoxib is a commonly used nonsteroidal anti-inflammatory drug that selectively inhibits cyclooxygenase-2. High-dose celecoxib (400 mg twice daily) for 14 days has been shown to reduce perihematomal edema and hematoma enlargement in patients with ICH, but without improvement in long-term functional outcome, which may be confounded by the heterogeneity of hematoma location. Low-dose celecoxib may be an effective management for symptoms caused by perihematomal edema in patients with ICH, particularly those involving the thalamus.enBrain edema; Celecoxib; Intracerebral hemorrhage.[SDGs]SDG1journal article354704092-s2.0-85128867222https://api.elsevier.com/content/abstract/scopus_id/85128867222